secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2023-06-12T23:59:59+00:00
Accession:  0001104659-23-070151
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics treats first lymphoma patient in Phase 1 APOLLO trial of MT-601
--------------------------------------------------------------------------------

- First patient dosed at 200 million cells; no treatment-related adverse events after 18 days.
- Trial enrolls up to 30 patients across 8 U.S. sites for lymphoma patients relapsed after or ineligible for anti-CD19 CAR T therapy.
- MT-601 targets six tumor antigens; prior TACTAL study showed durable responses with a five-antigen product.
- Nonclinical data from May 2023 showed MT-601 inhibited lymphoma cells regardless of CD19 expression and overcame CAR T resistance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923070151/0001104659-23-070151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923070151/tm2317378d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-070151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer